Fernanda Mosele received her MD from the Universidad of Buenos Aires in 2007. She then pursued specialized training in Clinical Oncology at the Universidad Católica Argentina in Buenos Aires. Dr Mosele worked as medical oncologist in Buenos Aires and dedicated her expertise to patient care until 2018, when her passion for translational research led her to join the renowned Gustave Roussy in Villejuif. Initially, she focused on the prognosis and treatment outcomes of patients with metastatic breast cancer and PIK3CA mutations. In 2020, she played a pivotal role in formulating recommendations for the utilization of next-generation sequencing (NGS) in the treatment of metastatic cancers, a seminal work with the ESMO Precision Medicine Group published the same year. Dr. Mosele further honed her expertise in precision medicine through postgraduate studies at the Université Paris-Saclay. Currently, Dr. Mosele leads cutting-edge biomarker research and precision medicine initiatives as a medical oncologist at Gustave Roussy, specializing in the treatment of breast cancer patients. She is an integral part of a comprehensive institutional program dedicated to clinical and translational research on antibodies-drug conjugates and drug development. Dr. Mosele recently published a pioneering study in Nature Medicine as the lead author, unraveling the mechanisms of action and resistance to Trastuzumab Deruxtecan. Additionally, she leads phase I-III clinical trials evaluating targeted therapies for advanced breast cancer.

Alexandre BOBARD obtained a PhD from Paris VI University in 2005 focused on metabolic disorders, and an EMBO long-term postdoctoral fellowship at ETH-Zürich for a project of pancreatic cancer biomarker. He then joined Institut Pasteur-Paris where he has set-up a research team in the field of cancer immunology, after an initial postdoc on bacterial infection and antibiotic resistance. The last 8 years he became general manager of the SIRIC (Site of Integrated Research in Cancerology) program of Institut Gustave Roussy led successively by Jean-Charles Soria and Eric Deutsch. In parallel, he co-created the yearly international conference ImmunoRad on radiotherapy/immunotherapy combinations in collaboration with Weill Cornell Medicine-NYC. His career has been constantly characterized by a wide array of biological approaches, and a focus on multiple different human diseases from diabetes, obesity, atherosclerosis to bacterial infection, and for the last 12 years cancer. The accumulated experience in various fields and pathologies, the use of many different technologies, the yearly travel to foreign conferences and prestigious research institutions provide him with a 360° view of medical biology research, as reflected by his 15 publications on very diverse topics. Years after years, he got closer and closer to the clinic, where he now brings his full expertise to therapeutic innovation in oncology.

Jerome Salmon obtained a PhD from the Paris VII University in 2003. His research studies at the Pasteur Institute were dedicated to the analysis of the immunogenetic and viral factors controlling the evolution of papillomavirus-associated tumors. He performed his postdoctoral training at the Johns Hopkins University School of Medicine in Baltimore, were he contributed to the large-scale identification of T cell epitopes in NIAID category A-C pathogens for the development of epitope-based vaccines. He later joined the Gustave Roussy Cancer Campus, and explored the immunoregulatory properties of retroviral and filoviral envelope proteins. He is now working on precision medicine for advanced pediatric solid cancers, focusing on the identification of novel tumor antigens and immunosuppressive factors for the development of antibody- and T cell-based therapeutics.